Browsing Tag
Niktimvo
2 posts
Incyte (Nasdaq: INCY) Q2 2026 revenue jumps 38% as CMS Opzelura settlement lifts headline growth
Incyte Q2 revenue jumped 38% on a $246m CMS Opzelura benefit, but the underlying growth line and $1.27bn Vega charge redraw the 2026 investment case.
Niktimvo FDA approval brings new hope for chronic graft-versus-host disease patients
The U.S. Food and Drug Administration (FDA) has approved Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody, for treating chronic graft-versus-host…